Ocular Therapeutix (OCUL) Current Deferred Revenue (2013 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Current Deferred Revenue of $14.0 million for Q2 2026, little changed year-over-year from $14.0 million in Q2 2025, and little changed on a QoQ basis from $14.0 million in Q1 2026.
Ocular Therapeutix (OCUL) Current Deferred Revenue (2013 - 2026) Analysis & Trends
Ocular Therapeutix has reported Current Deferred Revenue for 9 years, with the latest figure at $14.0 million in Q2 2026.
- Current Deferred Revenue for Q2 2026 came in at $14.0 million, changed 0.0% year-over-year; the trailing twelve-month figure through Jun 2026 was $14.0 million (changed 0.0% YoY), and the FY2025 annual result was $14.0 million, down 0.91% from the prior year.
- Current Deferred Revenue was little changed at $14.0 million in Q2 2026, from $14.0 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $14.6 million in Q2 2023 and troughed at $13.8 million in Q1 2023.
- A 5-year average of $14.2 million and a median of $14.1 million in 2022 frame the typical range for Current Deferred Revenue.
- The widest annual swing landed in 2022, when Current Deferred Revenue climbed 7.41%; it then fell 3.55% in 2023.
- A 5-year view of Current Deferred Revenue shows it stood at $14.0 million in 2022, then gained by 3.06% to $14.4 million in 2023, then retreated by 1.82% to $14.1 million in 2024, then retreated by 0.91% to $14.0 million in 2025, then changed by 0.0% to $14.0 million in 2026.
- Per Business Quant data, the three most recent Current Deferred Revenue figures were $14.0 million in Q2 2026, $14.0 million in Q1 2026, and $14.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.00 Mn |
| Mar 31, 2026 | 14.00 Mn |
| Dec 31, 2025 | 14.00 Mn |
| Sep 30, 2025 | 14.00 Mn |
| Jun 30, 2025 | 14.00 Mn |
| Mar 31, 2025 | 64,000.00 |
| Dec 31, 2024 | 14.13 Mn |
| Sep 30, 2024 | 190,000.00 |
| Jun 30, 2024 | 269,000.00 |
| Mar 31, 2024 | 14.33 Mn |
| Dec 31, 2023 | 255,000.00 |
| Sep 30, 2023 | 317,000.00 |
| Jun 30, 2023 | 391,000.00 |
| Mar 31, 2023 | 463,000.00 |
| Dec 31, 2022 | 576,000.00 |
| Sep 30, 2022 | 603,000.00 |
| Jun 30, 2022 | 1.19 Mn |
| Mar 31, 2022 | 1.21 Mn |
| Dec 31, 2021 | 13.00 Mn |
| Dec 31, 2015 | 42,000.00 |